| scholarly article | Q13442814 |
| P50 | author | Irina Grigorieva | Q64995851 |
| P2093 | author name string | Y Ivanov | |
| A Afanasiev | |||
| V Grigoriev | |||
| S Tkachenko | |||
| N Lermontova | |||
| S Bachurin | |||
| E Bukatina | |||
| N Zefirov | |||
| S Sablin | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | histamine antagonist | Q324089 |
| P304 | page(s) | 425-35 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer | |
| P478 | volume | 939 |
| Q30411257 | A randomized, placebo-controlled trial of latrepirdine in Huntington disease |
| Q26781560 | A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions |
| Q37681370 | Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease? |
| Q33592247 | Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo |
| Q35041190 | Alzheimer's disease and age-related memory decline (preclinical) |
| Q37739810 | Alzheimer's disease: strategies for disease modification |
| Q36103515 | Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). |
| Q90220831 | Anticholinesterase and Antioxidant Activity of New Binary Conjugates of γ-Carbolines |
| Q64077918 | Conjugates of methylene blue with γ-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases |
| Q38603960 | Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium |
| Q34222721 | Current and emerging drug treatment options for Alzheimer's disease: a systematic review. |
| Q34551056 | Development of proneurogenic, neuroprotective small molecules |
| Q37765630 | Dimebolin in dementia |
| Q36304050 | Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. |
| Q41894148 | Dimebon disappointment |
| Q38624671 | Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. |
| Q42223308 | Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release |
| Q35957568 | Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice |
| Q24620801 | Discovery of a proneurogenic, neuroprotective chemical |
| Q35545974 | Drug development for Alzheimer's disease: recent progress |
| Q21202838 | Evaluation of Dimebon in cellular model of Huntington's disease |
| Q85044101 | Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds |
| Q42115187 | Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. |
| Q24186444 | Latrepirdine for Alzheimer's disease |
| Q36763793 | Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model |
| Q36469322 | Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain |
| Q35940409 | Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea |
| Q38168475 | Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases |
| Q40154119 | MH84: A Novel γ-Secretase Modulator/PPARγ Agonist--Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer's Disease |
| Q84020741 | Mechanism matters |
| Q90049866 | Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update |
| Q37466059 | Mitochondria: a therapeutic target in neurodegeneration |
| Q34016406 | Mitochondrial Drugs for Alzheimer Disease |
| Q38007107 | Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease |
| Q37356257 | Mitochondrial structural and functional dynamics in Huntington's disease |
| Q38184970 | Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces |
| Q36660216 | NMDA receptors in clinical neurology: excitatory times ahead |
| Q36119574 | Neurological disorders and therapeutics targeted to surmount the blood-brain barrier |
| Q36934762 | Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease |
| Q37736181 | Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease |
| Q30525849 | Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease |
| Q30525846 | Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis |
| Q38540347 | Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine). |
| Q24620383 | Novel therapeutics for Alzheimer's disease: an update |
| Q37326505 | Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps |
| Q37198579 | Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? |
| Q37358680 | Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs? |
| Q34557710 | Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease |
| Q47633396 | Pro-neurogenic, Memory-Enhancing and Anti-stress Effects of DF302, a Novel Fluorine Gamma-Carboline Derivative with Multi-target Mechanism of Action |
| Q39789745 | Progress in the development of new drugs in Alzheimer's disease |
| Q35617556 | Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. |
| Q37922766 | Role of serotonin in Alzheimer's disease: a new therapeutic target? |
| Q35765716 | Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease |
| Q38797404 | The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity |
| Q35376045 | The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys |
| Q47575208 | The age-related gliosis and accompanying deficit in spatial learning are unaffected by dimebon. |
| Q37441183 | The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? |
| Q34146766 | The rise and fall of Dimebon |
| Q81527536 | Therapeutic strategies for Alzheimer's disease |
| Q38908265 | Thiourea-catalyzed enantioselective iso-Pictet-Spengler reactions |
| Q30419992 | Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress |
| Q22241760 | Translatability scoring in drug development: eight case studies |
| Q45946941 | [Neuro-enhancement. Brain doping]. |
Search more.